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priately elevated glucagon and growth hormone concentrations in the basal and stimulated state (32, 34) , it was anticipated that an Speculation effect of a or P adrenergic blockage might be more apparent in this Sympathetic overactivity, documented in poorly controlled juvenile diabetic subjects may, via a receptors, be one of the mechanisms responsible for growth hormone hypersecretion in these subjects. Although the evidence suggesting a role for adrenergic METHODS stimuli in modulating glucagon secretion is compelling, the relative hypersecretion of glucagon in juvenile diabetics in response to SUBJECTS AND PROCEDURES arginine does not seem to be pridominately influenced by-either a or p adrenergic receptors alone.
Six juvenile diabetics, aged 11-16 years, and four normal children, 13-16 years. were each studied on three separate occasions with an Intravenous arginine infusion, given eithe; alone It has been firmly established that the adrenergic nervous or in conjunction with a (phentolamine) or P (propranolol) system, through the release of catecholamines, is capable of adrenergic blockade. At least 3 days elapsed between each study.
ADRENERGIC BLOCKADE IN DIABETES
In accordance with the Declaration of Helsinki informed written RESULTS consent was obtained from parents, and all studies were approved by the institutional Human Use Committee. All patients were admitted between 8 and 9 A M to the Clinical Study Center after an overnight fast and remained recumbent throughout the study. An intravenous scalp needle was inserted into a vein in each antecubital fossa and maintained patent with a slow drip of 0.85% saline. For the diabetics, the usual morning dose of insulin was omitted and given at the conclusion of the test together with lunch. After two baseline blood samples 30 min apart were drawn, each subject received arginine monohydrochloride 0.5 g/kg (maximum 25 g) as a 5% solution in 0.85 saline over 30 min. Blood samples were collected at 15-min intervals for the first hour and 30-min intervals for a second hour. A similar procedure was followed during the a or /3 blockade, when the patients were closely monitored by attaching them to a recording and constant display oscilloscope for standard limb electrocardiography, by close supervision, and by measurement of pulse and blood pressure.
The propranolol was given intravenously as a loading dose of 3 mg for those less than 50 kg and 5 mg for those more than 50 kg in weight, over 5 min commencing 15 min before arginine infusion, and continued for 1 hr at a dose of 0.08 mg/min by means of a Harvard constant infusion pump. An identical schedule was used for phentolamine given as a loading dose of 4 mg and followed by 0.4 mg/min for a further hour. Thus, in the studies ascertaining the role of adrenergic blockade, the loading dose and continuous infusion had been ongoing for 15 min before 0 time, i.e.. before the arginine infusion commenced, and extended for 15 min after arginine infusion had been completed.
ANALYTICAL T E C H N I Q U E S
Each blood sample of 4 ml was placed into chilled tubes containing EDTA and aprotinin (Trasylol), 2,000 U in 0.2 ml, promptly spun in a refrigerated centrifuge, and the plasma was separated and stored frozen at -20' until assayed. Each sample was analyzed for glucose by a glucose oxidase technique (24) , growth hormone in duplicate, by radioimmunoassay described previously (27) , and glucagon in duplicate by radioimmunoassay using the highly specific pancreatic glucagon antiserum GI-5, a technique from our laboratory described previously (31) . All the radioimmunoassay procedures for each hormone were determined in a single assay run to obviate interassay variability.
Statistical analysis employed Student's T-test, and, where appropriate, the paired T-test. Table I lists the details of the patients studied. There were no significant differences between the groups apart from fasting plasma glucose which was significantly elevated in the diabetic group. As a group, the diabetics could not be considered as being under good control; only one had fasting plasma glucuse within the normal range. Although the mean of all three fasting plasma glucose determinations is shown, this is a true reflection of the values on all occasions.
During /3 adrenergic blockade there was some slowing of the pulse in all patients but no?e was symptomatic. During a adrenergic blockade with phentolamine patients remained asymptomatic while recumbent, but all complained of nausea and dizziness upon standing up. These patients were found to have a difference of up to 30 mm Hg systolic blood pressure on assuming the erect posture; symptoms abated upon reclining, and subsequently the constant infusion dose was reduced by 4 mg (from 24 to 20 mg). Thus, clinically at least, there was evidence of effective adrenergic blockade. Apart from these side effects there were no major symptoms or sequelae in any of the paitents or subjects, and all returned to their usual state of health upon completion of each test.
Growth hormone responses are depicted in Figures I and 2 (Table 2 ). In the normal children a significant increment occurred at 30 and 45 min during the arginine alone or with P blockade ( P < 0.05) but during cu blockade the increment was no longer significant despite a mean peak value similar to that seen during arginine alone. A more striking effect of a adrenergic blockade was apparent in the diabetic group where the hyper-responsiveness of growth hormone release to arginine was suppressed, and no significant increment above basal was observed. The difference in response between arginine with or without cu blockade was significantly different at 15 ( P < 0.05) and 30 ( P < 0.01) min. P blockade tended to elevate mean basal growth hormone concentrations but because of marked individual variation and the large S E M there was no significant change.
Glucagon responses are depicted in Figures 3 and.4 . The basal value in all three tests ranged from 147 & 31 pg/ml to 214 =t 21 pg/ml in normal children, and 100 * 20 to 124 + 17 pg/ml in the diabetics. The difference in basal values between the normal and diabetic children was significant ( P < 0.05) only during the propranolol study, but not during any other time.
Neither the basal nor arginine stimulated glucagon concentrations were significantly affected by cu or / 3 blockade in normal or diabetic subjects (Fig. 3) . Despite the minor differences in basal values, the maximal increment in glucagon concentrations after ' Mean of all three determinations in the fasting state.
arginine stimulation was not different in normal or diabetic children, nor was it affected by a or P adrenergic blockade (Fig. 4) .
DISCUSSION
The role of the a adrenergic receptor in mediating growth hormone release is well established (2, 17) and hyper responsiveness of growth hormone release to a variety of stimuli has been reported previously in insulin-dependent diabetics (32) . T h e exaggerated response is restored toward normal upon instituting careful control of the diabetic state (15) . Since fasting blood glucose was significantly elevated in our group of diabetic children, they could not be considered under good control, and therefore, the hyper responsiveness of growth hormone release to arginine was expected. T h e abolition of this response by a blockade with phentolamine indicates that in addition to symptoms and signs of a NORMAL CHILDREN f4/ T S.E.M.
-ARGlNlNE ONLY @-Q ARGININE + PHENTOLAMINE T blockade, the dose employed was adequate to interfere with growth hormone release. Thus, it could be speculated that one of the mechanisms involved in the hyperresponsiveness of growth hormone release observed among poorly controlled diabetics is dependent on overactivity of the adrenergic nervous system affecting the a receptor. Support for this concept comes from studies showing that plasma and urinary catecholamines are elevated in juvenile diabetics under poor control (1, 5, 6) and that this can be reversed with adequate insulin therapy (6) . A lack of effect from the p blockade in further augmenting growth hormone release in the diabetics might be explained on the basis of already existing maximal stimulation of the a receptor via endogenous catecholamines, an assumption which requires further documentation. Alternatively, previous studies indicate that P blockade alone does not elevate growth hormone consistently (26) . ' A loading dose plus constant infusion of the blocking agent was given commencing 15 rnin before 0 time and extending to 15 min after terminating arginine. Arginine was infused over 30 rnin commencing at 0 time. TIME IN MINUTES  Fig. 3 . Effect of adrenergic blockade on arginine-induced glucagon secretion (picograms per milliliter) in normal and diabetic children. The blocking agent was infused for 15 min before and 15 after arginine infusion. No significant differences are present. Vertical lines indicate I SEM.
As described previously by Unger et al. (34) for adults, basal plasma glucagon concentrations, as well as the response to arginine, were similar in the normal and diabetic children, despite the higher glucose values of the latter. In normal adults, elevating blood glucose lowers basal glucagon and blunts the response to arginine (33) . Similarly, we have shown recently that in normal children (31) , or in children with carbohydrate intolerance associated with cystic fibrosis (21), elevation of blood glucose suppresses plasma glucagon concentrations. Thus, the basal glucagon values and the response to arginine of the diabetic children, in the face of coexisting hyperglycemia, is an inappropriate response of the pancreatic a cell and confirms previous findings. In contrast to the demonstration of a clear-cut effect of a adrenergic blockade on growth hormone, neither a nor 0 blockade had any appreciable effect on the glucagon response. The evidence supporting an influence of the adrenergic nervous system on glucagon secretion is very compelling, as recently reviewed (36) , but the precise role of the adrenergic receptors in mediating this response is disputed. Thus, in man, Gcrich r / ul. (13) have suggested that @ adrcncrgic stimulation augments basal glucagon secretion, and that a adrenergic stimulation diminishes glucagon secretion, although no change resulted from 0 blockade alone. These same authors have claimed elsewhere (1 1) that a but not 0 adrenergic blockade inhibits the stimulation of glucagon by catecholamines. More recently, Walter et al. (35) could not demonstrate any effect of sustained a or 0 adrenergic blockade in modifying the elevation of glucagon induced by prolonged fasting or insulin-induced hypoglycemia, situations in which a rise in endogenous catecholamines is to be expected. The present investigation in children also failed to demonstrate any appreciable effect of adrenergic blockade on basal and arginine stimulated glucagon secretion.
In those studies in which an effect of adrenergic blockade has been reported, it has been apparent within 10~-20 min. Since in our Fig. 4 . Lack of significant difference in maximal glucagon secretion between normal and diabetic children after arginine stimulation alone, or in the presence of (propranolol) or a (phentolamine) adrenergic blockade. The vertical lines indicate I SEM. studies the blocking agent was infused for at least 15 min before commencing arginine, and since an effect on growth hormone release by arginine was certainly apparent, we cannot invoke inadequate dose or duration of infusion to explain our results. Moreover, most of the conflicting reports have utilized the same antiserum to measure glucagon (30K), so that the use of our own antiserum in these studies, although a possible contributing factor, cannot be the sole reason for our failure to demonstrate an effect of adrenergic blockade. In view of the reports of elevations of plasma glucagon by direct neural stimulation, by states of stress, and by epinephrine and norepinephrine (36) , situations in which both a and P adrenergic receptors are stimulated, it is conceivable that both are involved in mediating glucagon secretion, without either one predominating. This would be compatible with the divergent reports, and with our findings. Finally, the stimulation of glucagon secretion by arginine does not appear to be mediated via a or p adrenergic receptors.
SUMMARY
The effects of adrenergic blockade on glucagon and growth hormone secretion were investigated in normal and diabetic children. Absolute hypersecretion of growth hormone and relative hypersecretion of glucagon was demonstrated in the diabetics. Adrenergic blockade significantly inhibited growth hormone secretion in both groups, whereas 0 adrenergic blockade had no effect. Neither a nor P adrenergic blockade influenced basal or argininestimulated glucagon secretion in the diabetic or normal subjects. Thus, a adrenergic receptors may be involved in the hypersecretion of growth hormone among diabetic subjects, but a predominant role for either adrenergic receptor alone cannot be implicated in the relative hypersecretion of glucagon after arginine infusion in diabetic children.
